This post hoc analysis of the CorLipid clinical trial based on a well-selected population of hospitalized patients with DM and suspected or known history of comorbid CAD who underwent coronary angiography, showed that higher levels of apoB, acylcarnitine ratio C4/C18:2, and HsTnT were associated with higher risk for the primary composite outcome of MACCE, repeat unplanned revascularization and cardiac-disease related hospitalizations. Here, APOB is linked to heart disorder.